1-(4-methoxyphenyl)-7-oxo-6-(4-piperidinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide | 543745-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-methoxyphenyl)-7-oxo-6-(4-piperidinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
• 英文别名: 1-(4-Methoxyphenyl)-7-oxo-6-piperidin-4-yl-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
• CAS: 543745-08-0
• 化学式: C₁₉H₂₃N₅O₃
• 分子量: 369.423
• InChiKey: LQMDVRWTEGQOMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-methoxyphenyl)-7-oxo-6-(4-piperidinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide 在 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 18.0h， 生成 1-(4-methoxyphenyl)-6-(1-{2-[(methylamino)methyl]phenyl}-4-piperidinyl)-7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  参考文献：
  名称：

  Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues

  摘要：

  The synthesis, SAR, pharmacokinetic profile, and modeling studies of both monocyclic and fused pyrazoles containing substituted N-arylpiperidinyl P4 moieties that are potent and selective factor Xa inhibitors will be discussed. Fused pyrazole analog 16a, with a 2'-methylsulfonylphenyl piperidine P4 group, was shown to be the best compound in this series (FXa Ki = 0.35 nM) based on potency, selectivity, and pharmacokinetic profile.

  DOI：

  10.1016/j.bmcl.2006.11.071
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶 在 palladium on activated charcoal 盐酸 、 五氯化磷 、 potassium tert-butylate 、 氨 、 氢气 、 copper diacetate 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 乙二醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 85.5h， 生成 1-(4-methoxyphenyl)-7-oxo-6-(4-piperidinyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
  参考文献：
  名称：

  Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues

  摘要：

  The synthesis, SAR, pharmacokinetic profile, and modeling studies of both monocyclic and fused pyrazoles containing substituted N-arylpiperidinyl P4 moieties that are potent and selective factor Xa inhibitors will be discussed. Fused pyrazole analog 16a, with a 2'-methylsulfonylphenyl piperidine P4 group, was shown to be the best compound in this series (FXa Ki = 0.35 nM) based on potency, selectivity, and pharmacokinetic profile.

  DOI：

  10.1016/j.bmcl.2006.11.071

文献信息

• Substituted amino methyl factor Xa inhibitors
  申请人：——

  公开号：US20030212054A1

  公开（公告）日：2003-11-13

  The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了替代氨甲基取代化合物及其衍生物，或其药用盐形式，这些化合物可用作因子Xa的抑制剂。
• HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR
  申请人：NORTH CHINA PHARMACEUTICAL COMPANY., LTD.

  公开号：US20170152259A1

  公开（公告）日：2017-06-01

  Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X is selected from a 3-9 membered carbon ring or a ring which is formed by 3-9 membered carbocyclic ring fused with benzo ring, and a 4-10 membered heterocyclic ring or a ring which is formed by 4-10 membered heterocyclic ring fused with benzo ring; Y and Z are independently selected from 4-9 membered saturated heterocyclic rings respectively; R 1-3 are independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 , CHO, COOH respectively, or selected from the group, optionally substituted by R 01 , consisting of C 1-10 alkyl, C 1-10 heteroalkyl, C 3-10 cyclohydrocarbyl, C 3-10 heterocyclohydrocarbyl, C 1-10 alkyl substituted by C 3-10 cyclohydrocarbyl or C 3-10 heterocyclohydrocarbyl, and C 1-10 heteroalkyl substituted by C 3-10 cyclohydrocarbyl or C 3-10 heterocyclohydrocarbyl. The compound can be used as an anticoagulant for treating and preventing thrombotic disorders, and can meet the real needs of selectivity and a potent inhibitor for coagulation Xa.
• US6949550B2
  申请人：——

  公开号：US6949550B2

  公开（公告）日：2005-09-27
• US9938272B2
  申请人：——

  公开号：US9938272B2

  公开（公告）日：2018-04-10